Posted by Michael Wonder on 07 Mar 2023
Shorla Oncology announces US FDA approval of nelarabine injection for the treatment of T-cell leukaemia
7 March 2023 - Nelarabine injection ensures access to a lifesaving treatment that historically has been in shortage.
Shorla Oncology today announced that the US FDA approved the company’s oncology drug, nelarabine injection, for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.
